Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, ...
A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...
Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...
Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...
(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback